lenalidomide has been researched along with dabrafenib in 2 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (dabrafenib) | Trials (dabrafenib) | Recent Studies (post-2010) (dabrafenib) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 825 | 107 | 808 |
| Protein | Taxonomy | lenalidomide (IC50) | dabrafenib (IC50) |
|---|---|---|---|
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.077 | |
| GTPase KRas | Homo sapiens (human) | 5.88 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.15 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.026 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0033 | |
| TGF-beta receptor type-1 | Homo sapiens (human) | 3.7 | |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | 0.126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
2 review(s) available for lenalidomide and dabrafenib
| Article | Year |
|---|---|
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |